Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | lysine (K)-specific methyltransferase 2A | Starlite/ChEMBL | No references |
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Neospora caninum | Multidomain chromatinic protein with the following architecture: 3x PHD-bromo-3xPHD-SET domain and associated cysteine cluster a | Get druggable targets OG5_130642 | All targets in OG5_130642 |
Schistosoma mansoni | mixed-lineage leukemia protein mll | Get druggable targets OG5_130642 | All targets in OG5_130642 |
Toxoplasma gondii | histone lysine methyltransferase SET1 | Get druggable targets OG5_130642 | All targets in OG5_130642 |
Schistosoma japonicum | ko:K09188 myeloid/lymphoid or mixed-lineage leukemia protein 3, putative | Get druggable targets OG5_130642 | All targets in OG5_130642 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0542 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0542 | 1 |
Schistosoma mansoni | mixed-lineage leukemia protein mll | 0.0009 | 0.0651 | 0.0651 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0542 | 1 |
Trichomonas vaginalis | helicase, putative | 0.0008 | 0.0542 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0542 | 1 |
Schistosoma mansoni | cpg binding protein | 0.0037 | 0.4688 | 0.4688 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0542 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 1 |
Schistosoma mansoni | mixed-lineage leukemia protein mll | 0.0005 | 0.0127 | 0.0127 |
Trichomonas vaginalis | chromodomain-helicase-DNA-binding protein, putative | 0.0008 | 0.0542 | 1 |
Schistosoma mansoni | cpg binding protein | 0.0035 | 0.4403 | 0.4403 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 1 |
Echinococcus granulosus | cpg binding protein | 0.0037 | 0.4688 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0004 | 0 | 0.5 |
Trichomonas vaginalis | chromodomain-helicase-DNA-binding protein, putative | 0.0008 | 0.0542 | 1 |
Echinococcus multilocularis | cpg binding protein | 0.0037 | 0.4688 | 1 |
Loa Loa (eye worm) | CXXC zinc finger family protein | 0.0035 | 0.4403 | 1 |
Toxoplasma gondii | histone lysine methyltransferase SET1 | 0.0066 | 0.8869 | 0.5 |
Schistosoma mansoni | cpg binding protein | 0.0037 | 0.4688 | 0.4688 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 1 |
Onchocerca volvulus | 0.0035 | 0.4403 | 0.5 | |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0542 | 1 |
Echinococcus multilocularis | histone lysine N methyltransferase MLL3 | 0.0011 | 0.0956 | 0.0754 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 1 |
Plasmodium falciparum | zinc finger protein, putative | 0.0004 | 0 | 0.5 |
Brugia malayi | CXXC zinc finger family protein | 0.0035 | 0.4403 | 1 |
Echinococcus granulosus | histone lysine N methyltransferase MLL3 | 0.0011 | 0.0956 | 0.0754 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | > 150 um | PUBCHEM_BIOASSAY: Luminescence Microorganism-Based Dose Confirmation HTS to Identify Inhibitors of Streptokinase Promotor Activity. (Class of assay: confirmatory) [Related pubchem assays: 1677 (Project Summary), 1662 (Primary HTS)] | ChEMBL. | No reference |
EC50 (functional) | > 150 um | PUBCHEM_BIOASSAY: Absorbance Microorganism-Based Dose Response HTS to Identify Inhibitors of Streptokinase Expression. (Class of assay: confirmatory) [Related pubchem assays: 1677 (Project Summary), 1902 (Retest at Dose), 1900 (Counter Screen), 1662 (Primary HTS)] | ChEMBL. | No reference |
Potency (functional) | 3.1623 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 14.1254 um | PUBCHEM_BIOASSAY: qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction. (Class of assay: confirmatory) [Related pubchem assays: 2698 (Summary assay.)] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 23.1093 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PubChem BioAssay. qHTS Assay for Activators of ClpP. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.